3D Printing MicroFactory for Amorphous Solid Dispersion formulations

The Poster was presented at CMAC Summer School 2024

Context and Aim of Work

This study utilised the HUB Additive-ManufacturingMicroFactory as an enabler for streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® as a superior polymer to form stable ASD formulation with Ritonavir.

The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

Conclusion

A novel integrated HME-3D printer, the HUB ‘Additive-Manufacturing-MicroFactory’ enabled streamlined manufacture and performance testing of ASD formulation consisting of Ritonavir in Soluplus® polymer. By altering the porosity of the tablet core through additive manufacturing, product performance equivalent to a commercial product was obtained.

Download the full study as PDF here:
3D Printing MicroFactory for Amorphous Solid Dispersion formulations

or read it here

Prasad, E., Hueckman, J., Bordos, E., Robertson, J., & Halbert, G. W. (2024). 3D printing MicroFactory for amorphous solid dispersion formulations. Poster session presented at CMAC Summer School 2024, Dunblane, United Kingdom.